Abstract
Data on myelodysplastic syndromes (MDS) are seldom collected by cancer registries and unbiased findings from population-based studies remain rare. We report detailed information on MDS in a well-defined French population in the period 1980-1990. The crude incidence rate was 3.2 per 100000 per year and no significant change in incidence was noted in the study period. The sex ratio was 1.9 and the male predominance was present in all age groups. We observed a rise in incidence after 60 years of age but no significant change in incidence of MDS as a whole was observed over the period studied. Refractory anaemia with excess of blasts (RAEB) was the most frequent subtype. Overall 5 year transformation rate of MDS was 31% (+/- 4%) but it was 100% in RAEB in transformation. The observed 5 year survival rate was 23% +/- 3% and the corresponding corrected rate was 33%. The prognosis of RAEB in transformation was worse than the prognosis of other subtypes (P < 0.01). Discrepancies with epidemiological data from other European countries are discussed.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aul C., Gattermann N., Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992 Oct;82(2):358–367. doi: 10.1111/j.1365-2141.1992.tb06430.x. [DOI] [PubMed] [Google Scholar]
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982 Jun;51(2):189–199. [PubMed] [Google Scholar]
- Carli P. M., Milan C., Lange A., Devilliers E., Guy H., Faivre J. Haematopoietic malignancies in Côte d'Or (France): a population based study. Br J Cancer. 1986 Jun;53(6):811–815. doi: 10.1038/bjc.1986.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fenaux P., Jouet J. P., Zandecki M., Lai J. L., Simon M., Pollet J. P., Bauters F. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol. 1987 Jan;65(1):101–106. doi: 10.1111/j.1365-2141.1987.tb06142.x. [DOI] [PubMed] [Google Scholar]
- Janssen J. W., Buschle M., Layton M., Drexler H. G., Lyons J., van den Berghe H., Heimpel H., Kubanek B., Kleihauer E., Mufti G. J. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1989 Jan;73(1):248–254. [PubMed] [Google Scholar]
- Kerkhofs H., Hermans J., Haak H. L., Leeksma C. H. Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases. Br J Haematol. 1987 Jan;65(1):73–81. doi: 10.1111/j.1365-2141.1987.tb06138.x. [DOI] [PubMed] [Google Scholar]
- Lambertenghi-Deliliers G., Orazi A., Luksch R., Annaloro C., Soligo D. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol. 1991 Jun;78(2):161–166. doi: 10.1111/j.1365-2141.1991.tb04411.x. [DOI] [PubMed] [Google Scholar]
- Phillips M. J., Cull G. M., Ewings M. Establishing the incidence of myelodysplasia syndrome. Br J Haematol. 1994 Dec;88(4):896–897. doi: 10.1111/j.1365-2141.1994.tb05138.x. [DOI] [PubMed] [Google Scholar]
- Reizenstein P., Dabrowski L. Increasing prevalence of the myelodysplastic syndrome. An international Delphi study. Anticancer Res. 1991 May-Jun;11(3):1069–1070. [PubMed] [Google Scholar]
- Tricot G., De Wolf-Peeters C., Hendrickx B., Verwilghen R. L. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol. 1984 Jul;57(3):423–430. doi: 10.1111/j.1365-2141.1984.tb02916.x. [DOI] [PubMed] [Google Scholar]
- Williamson P. J., Kruger A. R., Reynolds P. J., Hamblin T. J., Oscier D. G. Establishing the incidence of myelodysplastic syndrome. Br J Haematol. 1994 Aug;87(4):743–745. doi: 10.1111/j.1365-2141.1994.tb06733.x. [DOI] [PubMed] [Google Scholar]